Hodgkin Disease: all 914 studies
Page 6 of 10. Open to participants first (136), then studies with results posted, then the rest; newest registration first within each.
- Brentuximab Vedotin and Nivolumab in Treating Patients With Early Stage Classic Hodgkin LymphomaActive, not recruitingNCT03712202Phase 2
- Anti-PD-1 and Chemotherapy for R/R Hodgkin LymphomaCompletedNCT03664323
- Study of GLS-010 Injection in the Treatment of Classical Hodgkin's LymphomaStatus unknownNCT03655483Phase 2
- Cytokine-Treated Veto Cells in Treating Patients With Hematologic Malignancies Following Stem Cell TransplantActive, not recruitingNCT03622788Phase 1/2
- Avelumab in the Frontline Treatment of Advanced Classical Hodgkin Lymphoma - a Window StudyActive, not recruitingNCT03617666Phase 2
- The Efficacy of Salvage BGD With autoSCT Consolidation in Advanced Classical HL Patients Not Responding to ABVDCompletedNCT03615664Phase 2
- Study to Evaluate the Safety and Efficacy of a Combination of Favezelimab (MK-4280) and Pembrolizumab (MK-3475) in Participants With Hematologic Malignancies (MK-4280-003)TerminatedNCT03598608Phase 1/2
- Study Of Nivolumab Alone, Or In Combination With Vinblastin In Patients With Classical Hodgkin LymphomaCompletedNCT03580408Phase 2
- BrEPEM-LH-22017 for Older Patients With Untreated Hodgkin Lymphoma (HL)Active, not recruitingNCT03576378Phase 1/2
- BV After Allogeneic Hematopoietic Stem Cell TransplantationStatus unknownNCT03540849Phase 2
- Elderly Hodgkin Lymphoma Patients Treated With ChemoradiotherapyStatus unknownNCT03535948
- OPTmizing Advanced Stage HodgkIn LymphoMa patIentS TherapyStatus unknownNCT03527628Phase 2
- Haploidentical Stem Cell Transplant with Prophylactic Natural Killer DLI for Lymphoma, Multiple Myeloma, and CLLCompletedNCT03524235Phase 1
- A Study of CS1001 in Subjects With Relapsed or Refractory Classical Hodgkin LymphomaCompletedNCT03505996Phase 2
- Abscopal Effect of Radiotherapy and Nivolumab in Relapsed Hodgkin Lymphoma After Anti-PD1 TherapyActive, not recruitingNCT03480334Phase 2
- Dose Escalation Study of CLR 131 in Pediatric Relapsed/Refractory Malignant Tumors Including Neuroblastoma and SarcomasActive, not recruitingNCT03478462Phase 1
- Brentuximab Vedotin as Alternative to the Autologous Stem Cell Transplantation in Relapsed and Refractory Classical Hodgkin's Lymphoma (BASALT)Status unknownNCT03474133Phase 2
- Safety and Efficacy Study of Tenalisib (RP6530) in Combination With Pembrolizumab in Relapsed or Refractory cHLTerminatedNCT03471351Phase 1
- Unicentric Retrospective Analysis of a Cohort of 602 Young Adult and Adolescent Patients (AJA), Aged 15 to 30 Years, With Haematological Malignancies, and Managed Between 2000 and 2016CompletedNCT03469921
- Patient-reported and Clinical Outcomes in Adults With Relapsed or Refractory Hodgkin's Lymphoma Receiving Brentuximab VedotinStatus unknownNCT03440788
- Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast CancerTerminatedNCT03432741Phase 1
- Safety, Tolerability, PK/PD of FE 203799 in Adults With LymphomasWithdrawnNCT03417765Phase 1/2
- Safety and Efficacy of Pembrolizumab (MK-3475) in Children and Young Adults With Classical Hodgkin Lymphoma (MK-3475-667/KEYNOTE-667)Active, not recruitingNCT03407144Phase 2
- Obstructive Sleep Apnea in Survivors of Hodgkin Lymphoma Treated With Thoracic RadiationActive, not recruitingNCT03361020
- Treatment With Nivolumab at the Fixed Dose 40 mg (Nivo40) in Patients With Relapsed/Refractory Hodgkins LymphomaCompletedNCT03343665Phase 1/2
- A Study of Safety and Efficacy of Nivolumab and Bendamustine (NB) in Patients With Relapsed/Refractory Hodgkin's LymphomaCompletedNCT03343652Phase 1/2
- ANIMATE: Phase II Study of Nivolumab Monotherapy for Relapsed/Refractory Hodgkin LymphomaActive, not recruitingNCT03337919Phase 2
- A Phase II Study to Determine Pembrolizumab as Frontline Treatment of Patients With Hodgkin LymphomaActive, not recruitingNCT03331731Phase 2
- GRAVITAS-119: Itacitinib in Combination With Calcineurin Inhibitor-Based Interventions for the Prophylaxis of Graft-Versus Host DiseaseTerminatedNCT03320642Phase 1
- Brentuximab Vedotin and Lenalidomide in Patients With Relapsed/ Refractory T-cell Lymphoma or Hodgkin LymphomaCompletedNCT03302728Phase 1
- Non-interventional, Long-term Follow-up of Subjects Who Completed ApoGraft-01 StudyStatus unknownNCT03260101
- Olaparib and High-Dose Chemotherapy in Treating Patients With Relapsed or Refractory Lymphomas Undergoing Stem Cell TransplantCompletedNCT03259503Phase 1
- Low Dose Plerixafor Plus G-CSF in Mobilizing Stem Cells for Autologous Peripheral Blood TransplantationStatus unknownNCT03244930Phase 2
- Study of Brentuximab Vedotin Plus TAK228 for Relapsed/Refractory Classical Hodgkin Lymphoma, Anaplastic Large Cell Lymphoma and Other CD30+Peripheral T-Cell LymphomasWithdrawnNCT03205891Phase 1
- Safety of Allogeneic Hematopoietic Cell Transplantation (HCT) For Patients With Classical Hodgkin Lymphoma (CHL) Treated With NivolumabCompletedNCT03200977
- Study to Assess the Safety of Nivolumab in the Treatment of Metastatic Melanoma, Lung Cancer, Renal Cancer, Squamous Cell Carcinoma of the Head and Neck, and Chronic Hodgkin Lymphoma in Adults in MexicoWithdrawnNCT03161613
- FIL Study on ABVD DD-DI as Upfront Therapy in HL.CompletedNCT03159897Phase 3
- ⁸⁹Zr-Df-IAB22M2C PET/CT in Patients With Selected Solid Malignancies or Hodgkin's LymphomaCompletedNCT03107663Phase 1
- PD-1 Knockout EBV-CTLs for Advanced Stage Epstein-Barr Virus (EBV) Associated MalignanciesStatus unknownNCT03044743Phase 1/2
- Prospective Comparison Between FDG-PET/MR and FDG-PET/CT in Classical Hodgkin Lymphoma and DLBC Non-Hodgkin LymphomaStatus unknownNCT03042247
- A(B)VD Followed by Nivolumab as Frontline Therapy for Higher Risk Patients With Classical Hodgkin Lymphoma (HL)Active, not recruitingNCT03033914Phase 1/2
- Brentuximab Vedotin, Cyclosporine, and Verapamil Hydrochloride in Treating Patients With Relapsed or Refractory Hodgkin LymphomaCompletedNCT03013933Phase 1
- Nivolumab and AVD in Early-stage Unfavorable Classical Hodgkin LymphomaCompletedNCT03004833Phase 2
- Haploidentical BMT With Post-Transplant Cyclophosphamide and BendamustineCompletedNCT02996773Phase 1
- Nivolumab With Epstein Barr Virus Specific T Cells (EBVSTS), Relapsed/Refractory EBV Positive Lymphoma (PREVALE)CompletedNCT02973113Phase 1
- Effect of Product Related Factors on Platelet Concentrate Transfusion Response in Patients With Hematologic MalignaciesCompletedNCT02885038
- Busulfan, Fludarabine Phosphate, and Post-Transplant Cyclophosphamide in Treating Patients With Blood Cancer Undergoing Donor Stem Cell TransplantActive, not recruitingNCT02861417Phase 2
- Hodgkin Lymphoma Molecular Profiling and Clinical Outcomes in U.S. Community Oncology PracticesCompletedNCT02856646
- Detection and Prognostic Value of Recurrent XPO1 Mutations of Patients With Classical Hodgkin LymphomaCompletedNCT02815137Not applicable
- Social Inequalities in the Participation and Activity in Children and Adolescents With Hodgkin-lymphomaStatus unknownNCT02808520
- Genetic Study of Families With High Frequency of Hodgkin LymphomaCompletedNCT02795013
- Sirolimus and Mycophenolate Mofetil in Preventing GVHD in Patients With Hematologic Malignancies Undergoing HSCTTerminatedNCT02728700Phase 1
- Randomized Trial of G-CSF Alone Versus Intermediate-dose Ara-C Plus G-CSF Mobilization in Hodgkin's Lymphoma or Non-Hodgkin's LymphomaStatus unknownNCT02722733Phase 3
- Brentuximab Vedotin in Refractory/Relapsed Hodgkin Lymphoma Treated by ICECompletedNCT02686346Phase 1/2
- Study of Pembrolizumab (MK-3475) vs. Brentuximab Vedotin in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (MK-3475-204/KEYNOTE-204)CompletedNCT02684292Phase 3
- Study of the Combination of AFM13 and Pembrolizumab in Patients With Relapsed or Refractory Classical Hodgkin LymphomaCompletedNCT02665650Phase 1
- HD21 for Advanced StagesActive, not recruitingNCT02661503Phase 3
- Ibrutinib in Relapsed Nodular Lymphocyte-predominant Hodgkin Lymphoma (NLPHL)CompletedNCT02626884Phase 2
- Pilot Study of Non-Viral, RNA-Redirected Autologous T Cells in Patients With Refractory or Relapsed Hodgkin LymphomaTerminatedNCT02624258Early Phase 1
- Brazilian Prospective Hodgkin Lymphoma RegistryStatus unknownNCT02589548
- Study of Tinostamustine, First-in-Class Alkylating HDACi Fusion Molecule, in Relapsed/Refractory Hematologic MalignanciesCompletedNCT02576496Phase 1
- A Study of Brentuximab Vedotin in Patients With Hodgkin Lymphoma Unsuitable for Chemotherapy Due to Age, Frailty or Co-morbidityCompletedNCT02567851Phase 2
- Clinical Application of Polyethylene Glycol Liposome Doxorubicin (PLD) in Primary LymphomaStatus unknownNCT02526823Phase 4
- Thiotepa-based Conditioning for Allogeneic Stem-cell Transplantation (SCT) in Lymphoid MalignanciesStatus unknownNCT02507479Phase 2
- INCB040093 and INCB040093 Combined With Itacitinib (INCB039110) in Relapsed/Refractory Hodgkin LymphomaTerminatedNCT02456675Phase 2
- Bendamustine Study in Classical Hodgkin Lymphoma Patients Over 60 Treated by Prednisone, Vinblastine and DoxorubicinCompletedNCT02414568Phase 2
- Early Markers of Radiation-Induced Cardiac Injury in Hodgkin Lymphoma Treated With Radiation TherapyCompletedNCT02404818
- Brentuximab for Newly Diagnosed Hodgkin DiseaseCompletedNCT02398240Phase 2
- Gene-Modified HIV-Protected Stem Cell Transplant in Treating Patients With HIV-Associated LymphomaWithdrawnNCT02378922Phase 1
- Defining PET / CT Protocols With Optimized F18-FDG (Fluorodeoxyglucose) Dose, Focusing on Reduced Radiation Dose and Improved Image QualityCompletedNCT02378337
- Safety Study of SEA-CD40 in Cancer PatientsTerminatedNCT02376699Phase 1
- HIV-Resistant Gene Modified Stem Cells and Chemotherapy in Treating Patients With Lymphoma With HIV InfectionWithdrawnNCT02343666Phase 1
- GHSG-AFM13 An Open-label, Multicenter Phase II Trial With AFM13 in Patients With Relapsed or Refractory Hodgkin LymphomaCompletedNCT02321592Phase 2
- Brentuximab Vedotin as Consolidation Treatment in Patients With Stage I/II HL and PET Positivity After 2 Cycles of ABVDCompletedNCT02298283Phase 2
- Brentuximab Vedotin Associated With Chemotherapy in Untreated Patients With Hodgkin Lymphoma.CompletedNCT02292979Phase 2
- Phase I/II Feasibility Study Combining Brentuximab Vedotin With Second Line Salvage Chemotherapy (DHAP) in Hodgkin Lymphoma PatientsStatus unknownNCT02280993Phase 1
- CD19 Redirected Autologous T Cells for Hodgkin LymphomaTerminatedNCT02277522Early Phase 1
- Brentuximab Vedotin Followed by ABVD in Patients With Previously Untreated Hodgkin LymphomaStatus unknownNCT02275598Phase 2
- A Longitudinal Assessment of Frailty in Young Adult Survivors of Childhood CancerActive, not recruitingNCT02256137
- Everolimus and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin LymphomaTerminatedNCT02254239Phase 1
- Dose-dense ABVD First Line Therapy in Early Stage Unfavorable Hodgkin's LymphomaCompletedNCT02247869Phase 2
- BRENTUXIMAB VEDOTIN as Pre-ASCT Induction Therapy in R/R HL Patients Non Responding to IGEVCompletedNCT02244021Phase 2
- Brentuximab Vedotin in Pre-transplant Induction and Consolidation for Relapsed or Refractory Hodgkin LymphomaCompletedNCT02243436Phase 1/2
- Everolimus and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory Hematologic CancerCompletedNCT02240719Phase 1
- Brentuximab Vedotin in the Elderly Hodgkin Lymphoma Patients at First Relapse or With Primary Refractory Disease.CompletedNCT02227433Phase 2
- A Safety and Tolerability Study of CDX-301 With or Without Plerixafor for Stem Cell Mobilization in Matched Related Allogeneic Donor/Recipient Sibling Transplant PairsTerminatedNCT02200380Phase 2
- Brentuximab Vedotin or B-CAP in the Treatment of Older Patients With Newly Diagnosed Classical Hodgkin LymphomaCompletedNCT02191930Phase 2
- Intra-Osseous Co-Transplant of UCB and hMSCCompletedNCT02181478Early Phase 1
- Phase I Study of Romidepsin, Gemcitabine, Oxaliplatin, and Dexamethasone in Patients With Relapsed/Refractory Aggressive LymphomasCompletedNCT02181218Phase 1
- CPI-613 and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma or Hodgkin LymphomaCompletedNCT02168140Phase 1
- JAK-inhibition in Recurrent Classical Hodgkin LymphomaCompletedNCT02164500Phase 2
- Novel PI3K Delta Inhibitor TGR-1202, in Combination With Brentuximab Vedotin for Hodgkin's Lymphoma PatientsCompletedNCT02164006Phase 1
- Immunotherapy Following Reduced Intensity Conditioning and Allogeneic Stem Cell Transplant for Poor Risk CD30+ Hodgkin Lymphoma PatientsStatus unknownNCT02098512Phase 1/2
- Pilot Study Exploring the Use of Hyperbaric Oxygen in Autologous Peripheral Blood Stem Cell TransplantationStatus unknownNCT02087657Not applicable
- Breast-Sparing Proton Therapy for Hodgkin's DiseaseTerminatedNCT02070393Early Phase 1
- TARC After alloSCT in Hodgkin's LymphomaCompletedNCT02069639
- Occupational Status and Hematological DiseaseCompletedNCT02057185
- Open-label Clinical Trial to Investigate the Safety and Tolerability of Allogeneic B-cell Concentrates for Immune Reconstitution After Allogeneic Stem Cell Transplantation Measured as Response to a Antedated Single VaccinationStatus unknownNCT02007811Phase 1/2
- Dietary and Exercise Interventions in Preventing Cardiovascular Disease in Younger Survivors of Leukemia, Lymphoma, or Brain TumorsWithdrawnNCT02000986Not applicable
- Pilot Study of Ruxolitinib in Relapsed or Refractory Hodgkin Lymphoma and Primary Mediastinal Large B-cell LymphomaCompletedNCT01965119Phase 2